WHO Issues Warning Over Severe Shortage of Weight-Loss Medications
Under 10% of patients who could benefit from obesity jabs such as Wegovy have access to them, states the global health agency as it publishes its initial guidance on the drugs.
With more than one billion individuals worldwide currently classified as obese, it is advocating for increased and just availability to this class of drugs.
Based on projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"The latest guidance affirms that obesity is a lifelong illness that can be addressed with comprehensive and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are major hurdles to broad availability to the treatments that can help people shift substantial weight, explains the organization.
Skinny Jab Scarcity
Even in the current most optimistic outlook, the production of these medications would only suffice for about 100 million people – fewer than 10% of the global need, according to the WHO.
The advice calls on governments and firms to expand access, through measures including patent sharing.
Exclusive production rights on a key compound – the main component of the drug Wegovy – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Jabs Operate
These medications mimick a natural hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so individuals reduce food intake.
Patients commonly start to lose weight after several weeks of starting on the weekly injections.
Studies points to patients may see weight return after a year of halting the medication, because their normal food cravings return.
Being carrying excess weight elevates your chance for contracting health problems, like diabetes, heart disease, stroke, and some cancers.
Obesity affects people in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
